The life sciences, Brexit and the UK Government ’s Industrial Strategy

In this report, we highlighted the benefits that collaboration has delivered for European science, and ultimately how this has improved the health of patients and the public across the European Union. The study has already proven influential and was widely referenced in the Government’s recent Brexit position paper on its ambitions for UKscience and innovation published earlier this month, which included the aim of continued future collaboration with the EU. The Life Sciences Industrial Strategy In response to the Industrial Strategy, sector leaders from the life sciences, including the Association of Medical Research Charities (AMRC), led by Professor Sir John Bell, have produced a detailed report for the Government, theLife Sciences Industrial Strategy (LSIS). This advisory report, published on 30th August, contains a number of key recommendations to the Government for sustaining and growing the sector in the UK. We responded to the original consultation on the wider Industrial Strategy and were pleased to see recognition of both Arthritis Research UK, and musculoskeletal conditions throughout this recently published strategy, as well as support for the wider medical research charity sector. Now we are assessing the recommendations of the LSIS itself in detail, and have already responded through various channels, including submission of evidence to theHouse of Lords inquiry into the Industrial Strategy, as well as supporting the wider-sector response, coordinated by t...
Source: Arthritis Research UK - Category: Rheumatology Source Type: news